What Next for Qnexa?
FDA's Request Shakes Up Vivus Stock, Qnexa Timeline
By Tom Wall
Monday, January 24, 2011
A week after Vivus Inc. CEO Leland Wilson praised the FDA during a breakout session at the J.P. Morgan Healthcare conference, the agency's request for more data about the incidence of birth defects in children born to women using topiramate, a component in obesity treatment Qnexa (phentermine/topiramate), shook the company's stock and plans for August FDA approval and a late 2011 launch.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.